Novo Nordisk A/S
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read More
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled […]
Read More
Is Novo Nordisk a get? Wall Avenue banking companies weigh in — and one offers it 36% draw back
For a lot of traders, the pounds loss drug boom has boosted Danish pharmaceutical big Novo Nordisk ‘s appeal this calendar year — but just one financial investment bank has reservations. “Above the coming yr, we envisage sentiment to change, most likely originally as a final result of the launch of competitor Eli Lilly ‘s […]
Read More
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More
Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each — a […]
Read More
Patients regain weight after stopping Eli Lilly's Zepbound, study says
Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took Eli Lilly‘s weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released Monday. The data, which represents the full results from an […]
Read More
Five stocks to acquire just before the year finish, according to the professionals
Quite a few shares have observed enormous rallies this year as buyers turned bullish on sectors like Big Tech, biotech, electric powered cars, and weight decline drugs. As the year-conclusion nears, CNBC Pro requested a few fund managers for sectors — and stocks — they are bullish on in the guide-up to 2024. In this […]
Read More
Eli Lilly vs. Novo Nordisk: The professionals supply their verdict on the viral body weight-reduction stocks
It has been really a calendar year for both Eli Lilly and Novo Nordisk given the increase in excess weight-reduction drugs. Stocks of both pharmaceutical corporations have rallied this 12 months. Shares in Eli Lilly are up all over 60% yr-to-date, while its Danish counterpart Novo Nordisk has noticed a achieve of about 50%. As […]
Read More
Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues. Zepbound is […]
Read More
An EU wealth tax and the stop of U.S. capitalism: Just one bank’s ‘outrageous’ predictions for 2024
The Wall Avenue bronze Bull seems to be out to an vacant Broadway in Decreased Manhattan, New York, on Aug. 28, 2011, as Hurricane Irene hits the metropolis and tri-point out location with rain and significant winds. Stan Honda | Afp | Getty Photographs An EU prosperity tax, the “end of capitalism” in the U.S. […]
Read More